Governance of Programmable RNA Editing Technologies

1. Introduction

Programmable RNA editing technologies are biotechnology platforms that enable targeted modification of RNA molecules inside living cells. Depending on the platform, these technologies may correct disease-associated RNA sequences, alter protein production, modify RNA splicing, or temporarily change gene expression without permanently modifying the underlying DNA sequence.

Unlike conventional genome-editing technologies, which alter DNA, RNA editing generally targets the intermediate molecules through which genetic information is expressed. Some programmable RNA-editing systems use engineered guide RNAs to direct enzymes such as adenosine deaminases acting on RNA (ADAR) to selected RNA sequences. Other approaches use different enzymes or mechanisms to modify RNA bases or processing.

These technologies have potential applications in treating genetic disorders, neurological diseases, metabolic conditions, cancer, and other illnesses. However, they also raise important legal questions concerning patient safety, clinical-trial authorization, informed consent, genetic privacy, intellectual property, manufacturing quality, and equitable access.

Governance of programmable RNA editing technologies refers to the legal, regulatory, ethical, and institutional mechanisms used to ensure that these technologies are developed, tested, manufactured, and deployed responsibly.

An important distinction is that RNA editing is not identical to DNA genome editing. Laws and judicial decisions concerning CRISPR and gene therapy may provide useful analogies, but they must not automatically be treated as directly governing every RNA-editing platform.

2. Meaning and Scientific Background

2.1 What is programmable RNA editing?

RNA is a molecule that carries and processes genetic information within cells. RNA editing changes particular nucleotides or otherwise modifies RNA processing, potentially changing the protein produced or the biological activity of the transcript.

For example, an RNA-editing platform may be designed to correct a specific RNA sequence associated with a disease. The resulting correction may restore some normal protein function while leaving the patient's DNA unchanged.

The principal characteristics of these technologies include:

Target specificity: The system is designed to act on a selected RNA sequence.

Potential reversibility: RNA molecules are naturally degraded and replaced, so an edit may be temporary rather than permanent.

Programmability: Targeting components can be redesigned to recognize different RNA sequences.

Delivery dependence: The editing machinery must reach the relevant cells and intracellular compartments.

Biological uncertainty: Unintended editing, immune responses, altered protein expression, and delivery-related toxicity remain important safety considerations.

Reversibility should not be confused with complete safety. A temporary RNA alteration may still produce serious consequences, and repeated treatment may be necessary to maintain a therapeutic effect.

2.2 Major technological categories

A. ADAR-mediated RNA editing

A programmable targeting component directs an ADAR enzyme toward a selected RNA molecule. The enzyme can catalyse adenosine-to-inosine editing, which may change how cellular machinery interprets the RNA.

B. Engineered RNA-editing systems

These approaches use engineered targeting molecules, modified enzymes, or other molecular components to achieve selected RNA modifications. Their legal and safety assessment depends on the precise mechanism and delivery system.

C. RNA splicing modulation

Certain programmable RNA-targeting technologies alter how RNA segments are included or excluded during RNA processing. These techniques can change the resulting protein without necessarily editing an individual nucleotide.

D. RNA-targeted therapeutic platforms

Some systems target RNA to reduce, redirect, or otherwise alter gene expression. They may fall within broader RNA-therapeutic regulation even where they do not perform nucleotide editing in the strict scientific sense.

These categories must be distinguished because the risks, manufacturing requirements, evidence of effectiveness, and applicable regulatory pathways may differ.

3. Objectives of Governance

The principal objectives are:

Protect patients and research participants against foreseeable harm.

Ensure that clinical claims are supported by reliable scientific evidence.

Prevent unauthorized experimentation and misleading commercial promotion.

Establish clear responsibility for adverse events and defective products.

Protect sensitive genetic and health information.

Prevent misuse involving non-consensual biological intervention.

Encourage legitimate innovation while protecting public health.

Ensure fair access to safe and effective treatments.

Establish appropriate oversight of manufacturing, storage, distribution, and post-treatment monitoring.

Effective governance must cover the complete lifecycle, from laboratory research through clinical development, marketing authorization, clinical use, and long-term safety surveillance.

4. Legal and Regulatory Framework in India

India does not have a single statute exclusively devoted to programmable RNA editing. Its regulation depends on whether the technology is a medicinal product, a research tool, a genetically engineered biological system, or another regulated product or activity.

4.1 Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act, 1940, and applicable rules provide the principal statutory framework for the regulation of drugs and relevant biological products in India.

Where a programmable RNA-editing platform is developed as a therapeutic product, its sponsor must determine the applicable requirements for manufacture, clinical investigation, quality control, and marketing authorization.

The Central Drugs Standard Control Organisation (CDSCO) is a central regulatory authority involved in the assessment and authorization of regulated drugs and clinical trials.

4.2 New Drugs and Clinical Trials Rules, 2019

The New Drugs and Clinical Trials Rules, 2019, establish requirements relevant to clinical trials and new drugs within their scope.

For an investigational RNA-editing therapy, relevant issues include:

Permission to conduct a clinical trial, where required.

Ethical review by an appropriately constituted ethics committee.

Scientific justification for the proposed intervention.

Preclinical safety and pharmacological evidence.

Appropriate informed consent.

Monitoring and reporting of serious adverse events.

Compliance with applicable compensation requirements for trial-related injury or death.

Regulatory oversight of the investigational product.

A researcher's ability to perform RNA editing in a laboratory does not itself authorize administration of the system to human participants.

4.3 National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019

India's National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019, issued through the relevant national regulatory and research institutions, provide an important framework for gene-therapy development.

Their direct applicability to a particular RNA-editing product must be assessed according to its classification and mechanism. A platform that modifies RNA rather than DNA should not automatically be classified as a genome-editing product solely because it is programmable.

Nevertheless, the guidelines may offer relevant principles concerning product characterization, nonclinical studies, clinical development, manufacturing quality, and patient safety where the product falls within their scope.

4.4 Environment (Protection) Act, 1986, and the 1989 Biosafety Rules

The Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Micro-organisms, Genetically Engineered Organisms or Cells, 1989, establish controls for specified activities involving hazardous microorganisms and genetically engineered organisms or cells.

These rules may become relevant if an RNA-editing project uses genetically engineered cells, engineered organisms, or other biological materials within their scope.

However, a synthetic RNA therapeutic does not automatically become subject to every provision governing genetically engineered organisms merely because it contains a programmable biological component. The specific product, activity, and statutory definitions must be examined.

4.5 Indian Council of Medical Research ethical guidance

The Indian Council of Medical Research's ethical guidance for biomedical and health research involving human participants is relevant to research involving investigational RNA-editing interventions.

Ethical oversight should address the scientific necessity of the intervention, foreseeable risks, participant selection, informed consent, confidentiality, vulnerability, and the right to withdraw where applicable.

Ethical guidance must be read together with binding legislation and applicable regulatory conditions. It should not be treated as a substitute for statutory approval.

4.6 Data protection and genetic information

Programmable RNA-editing research may involve genomic sequencing, transcriptomic analysis, family medical histories, and other sensitive health information.

The Digital Personal Data Protection Act, 2023, and applicable rules and commencement provisions should be considered where identifiable digital personal data are processed. Other applicable medical-confidentiality, research, and contractual obligations may also be relevant.

Governance should establish lawful data collection, appropriate notice and consent where required, access controls, data minimization, secure storage, and responsible sharing of research information.

4.7 Recent regulatory developments

India's regulation of advanced cell and gene therapies is evolving. In 2026, the Government of India announced amendments to the Drugs Rules, 1945, bringing specified cell- and stem-cell-derived products, gene therapeutic products, and xenografts within an expanded Centrally License Approving Authority framework. The application of these amendments to a particular RNA-editing product depends on its legal classification. <Cite refs={["turn746724search7","turn746724search0"]}/>

This development reinforces the need to establish a product's regulatory category before commencing clinical development or commercialization.

5. International Regulatory Framework

5.1 United States

In the United States, the Food and Drug Administration (FDA) regulates drugs and biological products within its statutory jurisdiction. An investigational RNA-editing therapeutic may require an Investigational New Drug application and, if approved for marketing, compliance with the applicable drug or biologics requirements.

The FDA's January 2024 guidance, Human Gene Therapy Products Incorporating Human Genome Editing, addresses genome-editing products and recommends information concerning product design, manufacturing, testing, nonclinical safety, and clinical-trial design. Its direct scope concerns genome editing of human somatic cells; it is not a universal RNA-editing rule. Nevertheless, some of its safety and product-characterization principles may be relevant by analogy. <Cite refs={["turn746724search1"]}/>

5.2 European Union

In the European Union, an RNA-editing therapeutic may fall within the medicinal-products framework, including Regulation (EC) No. 726/2004 and Directive 2001/83/EC, depending on its classification and intended use.

If the product qualifies as an advanced therapy medicinal product, Regulation (EC) No. 1394/2007 may also become relevant. Classification must be determined on the characteristics of the product rather than the broad label of RNA editing.

5.3 World Health Organization

The World Health Organization's work on human genome editing emphasizes governance, transparency, scientific responsibility, international cooperation, and safeguards against irresponsible applications.

These principles provide useful ethical context for programmable RNA editing. However, guidance specifically concerning genome editing should not be misrepresented as a binding international convention or as a comprehensive legal code for RNA therapeutics.

5.4 International ethical principles

Internationally relevant principles include:

Respect for human dignity and autonomy.

Scientific validity and independent review.

Proportionate risk-benefit assessment.

Informed consent and protection of vulnerable participants.

Non-discrimination and equitable access.

Transparency in clinical research.

Accountability for adverse outcomes.

Protection of confidential biological information.

Their enforceability depends on the applicable treaties, national laws, regulatory conditions, and institutional rules.

6. Case Laws Relevant to Programmable RNA Editing

Important legal qualification: The following decisions establish legal principles relevant to biomedical innovation, consent, privacy, patentability, and environmental or product liability. They are not presented as judgments specifically deciding the legality of programmable RNA editing. Their relevance is analogical and depends on the facts and applicable jurisdiction.

Case 1: Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1

Court: Supreme Court of India.

Facts: The dispute arose from a medical procedure performed on a patient and the question of whether the patient's consent authorized the treatment actually undertaken.

Legal principle: The Supreme Court explained the requirements of valid informed consent in medical treatment. Consent must be real and voluntary, and the patient must receive information sufficient to understand the nature and purpose of the proposed intervention and its material risks. Consent to one procedure does not automatically authorize a substantially different procedure, subject to recognized exceptions.

Application to RNA editing: A patient enrolled in an RNA-editing clinical trial should be informed about the investigational nature of the treatment, known and uncertain risks, alternative treatments, potential lack of benefit, follow-up requirements, and relevant data use. Consent to ordinary treatment should not be treated as blanket permission for experimental molecular intervention.

Governance implication: Investigators and sponsors should maintain a clear consent process, document material disclosures, and explain uncertainty honestly.

Case 2: K.S. Puttaswamy v. Union of India, (2017) 10 SCC 1

Court: Supreme Court of India.

Facts: The case concerned whether privacy is protected as a fundamental right under the Constitution of India.

Legal principle: The Court recognized privacy as a constitutionally protected fundamental right, grounded in liberty and dignity under Part III of the Constitution.

Application to RNA editing: Development of RNA-editing therapies may require collection of genomic sequences, transcriptomic profiles, family histories, and treatment-response data. Such information can reveal intimate details about health and biological characteristics.

Governance implication: Research institutions and sponsors should apply appropriate safeguards for collection, use, storage, disclosure, and sharing of identifiable health information. Consent to participate in a clinical trial should not be confused with unlimited consent to commercialize or disclose a participant's biological data.

The precise statutory obligations must also be assessed under applicable data-protection and medical-confidentiality rules.

Case 3: Common Cause v. Union of India, (2018) 5 SCC 1

Court: Supreme Court of India.

Facts: The proceedings concerned end-of-life decision-making, patient autonomy, and the legal recognition of advance medical directives.

Legal principle: The judgment recognized the significance of dignity and patient autonomy in medical decision-making, including in the context of refusing life-sustaining treatment under legally prescribed safeguards.

Application to RNA editing: Experimental biotechnology may involve repeated treatment, uncertain outcomes, and substantial long-term monitoring. Patients should retain meaningful control over participation, subject to applicable legal and ethical requirements.

Governance implication: Consent processes should address withdrawal from research, future contact, ongoing sample use, and the limits of withdrawing data already incorporated into research or lawfully required records. The case does not itself establish a specific right to discontinue every aspect of a completed RNA-editing intervention.

Case 4: Vellore Citizens' Welfare Forum v. Union of India, (1996) 5 SCC 647

Court: Supreme Court of India.

Facts: The case involved industrial pollution from tanneries and environmental damage caused by the discharge of untreated effluents.

Legal principle: The Court recognized the precautionary principle and polluter-pays principle as important components of sustainable development.

Application to RNA editing: Environmental considerations may arise where research uses engineered biological production systems, genetically modified cells, viral delivery vectors, or potentially hazardous biological waste. The precise environmental regime depends on the materials and activity involved.

Governance implication: Developers should assess foreseeable environmental risks, establish safe waste-handling procedures, and comply with applicable biosafety and environmental requirements. The decision does not mean that every RNA-editing drug is inherently an environmental hazard.

Case 5: M.C. Mehta v. Union of India (Oleum Gas Leak Case), (1987) 1 SCC 395

Court: Supreme Court of India.

Facts: A hazardous industrial activity resulted in an oleum gas leak in Delhi.

Legal principle: The Supreme Court developed the doctrine of absolute liability for enterprises engaged in hazardous or inherently dangerous activities.

Application to RNA editing: A serious accident involving a hazardous manufacturing process, engineered biological materials, or another dangerous activity may raise questions of enterprise liability. The applicable cause of action will depend on the actual activity, the nature of the harm, and relevant statutory provisions.

Governance implication: Sponsors and manufacturers should establish effective containment, occupational safety, incident reporting, emergency procedures, and appropriate insurance and compensation arrangements. Absolute liability should not be assumed to apply automatically to every adverse reaction to an RNA-editing medicine.

Case 6: Novartis AG v. Union of India, (2013) 6 SCC 1

Court: Supreme Court of India.

Facts: The dispute concerned the patentability of a modified form of a known cancer medicine under Section 3(d) of the Patents Act, 1970.

Legal principle: The Court interpreted Section 3(d), including the requirement concerning enhanced therapeutic efficacy for certain new forms of known substances. The judgment is an important authority on India's pharmaceutical patentability standards.

Application to RNA editing: Companies may seek patents covering particular RNA-editing compositions, delivery technologies, formulations, or technical processes. Patentability must be assessed under the relevant statutory provisions, including novelty, inventive step, industrial applicability, and applicable exclusions.

Governance implication: A patent application should identify a legally patentable invention rather than assume that discovery of a naturally occurring RNA sequence, standing alone, creates an enforceable monopoly. The Novartis decision does not specifically decide the patentability of RNA-editing systems.

Case 7: Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)

Court: Supreme Court of the United States.

Facts: The litigation concerned patents relating to isolated BRCA1 and BRCA2 genes associated with hereditary breast and ovarian cancer.

Legal principle: The Court held that naturally occurring DNA segments are not patent-eligible merely because they have been isolated, while synthetically created cDNA may be patent-eligible subject to the distinction addressed in the judgment.

Application to RNA editing: The case illustrates the difference between discovering a naturally occurring biological sequence and developing a qualifying technical invention. RNA-editing developers must consider the relevant jurisdiction's rules for biological subject matter, engineered constructs, methods, and applications.

Governance implication: Patent protection should be evaluated separately from regulatory approval and ethical acceptability. A patent does not establish clinical safety, therapeutic efficacy, or permission to administer a product to patients.

Case 8: Moore v. Regents of the University of California, 51 Cal. 3d 120 (1990)

Court: Supreme Court of California, United States.

Facts: A patient challenged the use and commercialization of biological materials derived from his body without the disclosure and consent he alleged were required.

Legal principle: The court rejected the patient's conversion claim concerning the excised cells under the circumstances presented, while recognizing the significance of informed-consent and fiduciary-duty claims.

Application to RNA editing: Development programmes may involve patient-derived cells, tissue samples, RNA, or biological data used in research and commercialization. The legal rights associated with these materials vary by jurisdiction and the circumstances of collection and use.

Governance implication: Researchers should explain material research uses, commercial interests, sample retention, and data-sharing arrangements when required. Moore is a jurisdiction-specific decision and does not establish a universal rule that biological samples can always be commercialized without consent.

7. Comparative Summary of the Cases

The cases operate in different legal contexts. Together, they provide a framework for analyzing relevant legal questions, but they do not replace product-specific regulatory assessment or establish a single, comprehensive RNA-editing doctrine.

8. Governance Across the Technology Lifecycle

A sound governance framework should apply different safeguards at each stage of development.

8.1 Fundamental research

At the laboratory stage, governance should address institutional authorization, scientific integrity, biosafety, the use of biological materials, and the management of research data.

Institutional biosafety committees should review activities involving materials within their jurisdiction. Research involving human participants or identifiable human biological samples must also comply with the applicable ethical and legal requirements.

8.2 Preclinical development

Before first-in-human administration, sponsors should generate evidence appropriate to the proposed product and its mechanism. Important considerations include:

Intended RNA target and editing specificity.

Unintended RNA modifications and downstream biological effects.

Delivery-system toxicity and immune responses.

Dose, duration, and persistence of the biological effect.

Effects of repeated administration, where relevant.

Reproductive or developmental risks where scientifically applicable.

Appropriate nonclinical models and the limitations of those models.

The extent of testing should be proportionate to the product's characteristics, proposed indication, and anticipated risks.

8.3 Clinical trials

Clinical trials should be scientifically justified, independently reviewed, and authorized under the applicable regulatory framework.

Sponsors should establish procedures for adverse-event reporting, safety monitoring, protocol deviations, participant withdrawal, and protection against undue influence. Trial documents should clearly distinguish established evidence from experimental hypotheses.

8.4 Manufacturing and quality control

Manufacturers should establish suitable quality systems to ensure product identity, purity, potency, consistency, and stability.

For RNA-editing products, relevant quality attributes may include RNA sequence integrity, editing-system activity, delivery-system characteristics, contamination controls, and batch-to-batch consistency.

Applicable good manufacturing practice requirements should be identified according to the product's regulatory classification. A product cannot be considered safe merely because its molecular design is theoretically precise.

8.5 Marketing authorization and post-market surveillance

Before commercialization, the sponsor must obtain the required authorization. Post-market responsibilities may include adverse-event reporting, periodic safety review, product-quality investigations, and additional studies when required by the regulator.

Where a treatment has uncertain long-term effects, proportionate follow-up can help identify risks not detected during early clinical development.

9. Major Legal and Ethical Challenges

9.1 Unintended RNA editing

Programmable systems may act on unintended RNA molecules or produce unexpected biological effects. These possibilities complicate the assessment of therapeutic benefit and risk.

Governance response: Require validated analytical methods, appropriate specificity testing, transparent reporting, and risk-proportionate clinical monitoring.

9.2 Distinguishing RNA editing from genome editing

The distinction matters because RNA editing generally changes RNA rather than the DNA sequence, whereas genome editing targets DNA. However, a therapeutic product may contain additional components that trigger other regulatory requirements.

Governance response: Regulators should classify products according to their actual mechanism, composition, intended use, and risks rather than relying solely on broad technological labels.

9.3 Germline and reproductive applications

Although RNA editing does not ordinarily modify DNA, interventions involving reproductive cells, embryos, pregnancy, or developmental processes can raise significant ethical and legal issues. The risks depend on the specific intervention, and RNA editing should not automatically be equated with heritable genome editing.

Governance response: Require specific ethical and legal assessment of reproductive applications, including consent, potential effects on future offspring, and applicable restrictions.

9.4 Genetic privacy and commercialization

Biological information may reveal disease susceptibility, family relationships, and other sensitive characteristics. Commercial research may create additional questions about secondary use and data sharing.

Governance response: Establish clear data-use policies, access controls, appropriate participant information, retention schedules, and safeguards for authorized secondary research.

9.5 Intellectual property and affordability

Patent protection may encourage investment in new treatments but can also affect licensing, competition, and access.

Governance response: Apply patentability standards carefully, encourage appropriate licensing arrangements, and use applicable public-health and competition-law mechanisms where relevant.

9.6 Regulatory uncertainty

Different countries may classify similar products differently. An RNA-editing therapy may be regulated as a drug, biological product, or another category depending on the jurisdiction and product characteristics.

Governance response: Promote transparent classification procedures, early regulatory consultation, harmonized technical standards where feasible, and international cooperation.

10. Recommendations for an Effective Governance Model

An effective framework for programmable RNA editing should incorporate the following measures:

Technology-specific classification: Distinguish RNA editing, RNA-targeted gene regulation, and DNA genome editing.

Risk-based authorization: Match the level of oversight to the intended use, delivery mechanism, biological effects, and severity of potential harm.

Independent scientific review: Require competent assessment of efficacy, specificity, toxicity, and manufacturing quality.

Meaningful informed consent: Explain uncertainties, alternatives, material risks, and relevant data-use arrangements.

Clear liability rules: Identify responsibilities among sponsors, manufacturers, investigators, healthcare providers, and institutions.

Privacy safeguards: Protect identifiable biological and health information throughout research and treatment.

Post-market accountability: Establish monitoring, reporting, corrective action, and recall procedures where applicable.

Equitable access: Consider affordability, appropriate licensing, and access to effective therapies.

Transparent governance: Publish relevant regulatory decisions and safety findings to the extent permitted by law and legitimate confidentiality obligations.

Periodic review: Update standards as the science, evidence, and applicable law evolve.

11. Conclusion

Programmable RNA editing is an emerging therapeutic technology with the potential to alter RNA sequences or processing in ways that may benefit patients while avoiding permanent changes to DNA. Its clinical promise must nevertheless be evaluated alongside risks involving unintended biological effects, delivery systems, patient consent, data protection, product quality, and equitable access.

In India, the relevant legal framework may include the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, applicable biotechnology biosafety requirements, ethical guidance, and data-protection law. The precise obligations depend on the product's characteristics and regulatory classification.

The judicial decisions discussed above provide important principles concerning informed consent, privacy, autonomy, environmental precaution, liability, patentability, and biological materials. They should be used as analogical legal authorities, not misrepresented as direct judicial rulings on programmable RNA editing.

Ultimately, responsible governance requires scientific evidence, proportionate regulation, independent oversight, patient autonomy, clear accountability, and continuing safety monitoring. Such an approach can support legitimate innovation while protecting human dignity, public health, and confidence in emerging biotechnology.